In fact, FLT3 mutant AML cells treated with FLT3 inhibitors (AC220, quizartinib), activate an innate immune pathway via the interleukin-1 receptor-associated kinase 1 and 4 (IRAK1/4). This evidence concerns the gene IRAK1 and acute myeloid leukemia.